Protagonist Therapeutics Inc. (PTGX): Advancing Treatments for Autoimmune Diseases
State Street Corp's Strategic Acquisition in Protagonist Therapeutics Inc
TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $65
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
Protagonist Therapeutics Participates in a Conference Call With JPMorgan
Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
